XML 39 R11.htm IDEA: XBRL DOCUMENT
v3.19.2

Goodwill and Other Intangible Assets | 12 Months Ended
--- | ---
Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Other Intangible Assets | 4. Goodwill and Other Intangible Assets Goodwill The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions) | Pharmaceutical (1) |  | Medical (2) |  | Total
Balance at June 30, 2017 | $ | 2,939 |  |  | $ | 4,282 |  |  | $ | 7,221 |
Goodwill acquired, net of purchase price adjustments | 1 |  |  | 3,342 |  |  | 3,343 |
Foreign currency translation adjustments and other | 28 |  |  | 6 |  |  | 34 |
Goodwill divested with the sale of our China distribution business | (347 | ) |  | (54 | ) |  | (401 | )
naviHealth goodwill reclassified to assets held for sale | — |  |  | (509 | ) |  | (509 | )
Impairment | — |  |  | (1,372 | ) |  | (1,372 | )
Balance at June 30, 2018 | 2,621 |  |  | 5,695 |  |  | 8,316 |
Goodwill acquired, net of purchase price adjustments | 45 |  |  | 7 |  |  | 52 |
Foreign currency translation adjustments and other | (3 | ) |  | 13 |  |  | 10 |
Balance at June 30, 2019 | $ | 2,663 |  |  | $ | 5,715 |  |  | $ | 8,378 |
(1) | At June 30, 2019 and 2018, the Pharmaceutical segment accumulated goodwill impairment loss was $829 million.
(2) | At June 30, 2019 and 2018, the Medical segment accumulated goodwill impairment loss was $1.4 billion.
Fiscal 2018 The increase in the Medical segment goodwill during fiscal 2018 is primarily due to the Patient Recovery Business acquisition. Goodwill recognized in connection with the Patient Recovery Business acquisition primarily represents the expected benefits from certain synergies of integrating the business, the existing workforce of the acquired entity, and the expected growth from new customers. See Note 2 for further discussion of this acquisition. In conjunction with the preparation of our consolidated financial statements for fiscal 2018, we completed our annual quantitative goodwill impairment test, which we perform annually in the fourth quarter. Using a combination of income and market-based approaches (using a discount rate of 8.5 percent), the carrying value exceeded the fair value and resulted in an impairment charge of $1.4 billion related to our Medical Unit, which is included in impairments and loss on disposal of assets in our consolidated statements of earnings. Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements. The impairment was primarily driven by inventory and cost challenges within our Cordis business which furthered in the fourth quarter of fiscal 2018. This impairment charge did not impact our liquidity, cash flows from operations, or compliance with debt covenants. There was no tax benefit related to the goodwill impairment charge. The goodwill balance for our Medical Unit, after recognizing the impairment, was $4.3 billion at June 30, 2018. During fiscal 2018, goodwill was also reduced by $401 million and $509 million in connection with the sale of our China distribution business and reclassification of naviHealth's assets and liabilities to held for sale, respectively. See Note 2 for further discussion of this divestiture and assets held for sale. Other Intangible Assets The following tables summarize other intangible assets by class at June 30:
| 2019
(in millions) | Gross Intangible |  | Accumulated Amortization |  | Net Intangible |  | Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles: |  |  |  |  |  |  |
IPR&D, trademarks and other | $ | 22 |  |  | $ | — |  |  | $ | 22 |  |  | N/A
Total indefinite-life intangibles | 22 |  |  | — |  |  | 22 |  |  | N/A
Definite-life intangibles: |  |  |  |  |  |  |
Customer relationships | 3,562 |  |  | 1,517 |  |  | 2,045 |  |  | 14
Trademarks, trade names and patents | 672 |  |  | 295 |  |  | 377 |  |  | 14
Developed technology and other | 1,602 |  |  | 616 |  |  | 986 |  |  | 12
Total definite-life intangibles | 5,836 |  |  | 2,428 |  |  | 3,408 |  |  | 13
Total other intangible assets | $ | 5,858 |  |  | $ | 2,428 |  |  | $ | 3,430 |  |  | N/A
| 2018
(in millions) | Gross Intangible |  | Accumulated Amortization |  | Net Intangible
Indefinite-life intangibles: |  |  |  |  |
IPR&D, trademarks and other | $ | 62 |  |  | $ | — |  |  | $ | 62 |
Total indefinite-life intangibles | 62 |  |  | — |  |  | 62 |
Definite-life intangibles: |  |  |  |  |
Customer relationships | 3,513 |  |  | 1,191 |  |  | 2,322 |
Trademarks, trade names and patents | 667 |  |  | 246 |  |  | 421 |
Developed technology and other | 1,562 |  |  | 454 |  |  | 1,108 |
Total definite-life intangibles | 5,742 |  |  | 1,891 |  |  | 3,851 |
Total other intangible assets | $ | 5,804 |  |  | $ | 1,891 |  |  | $ | 3,913 |
Total amortization of intangible assets was $531 million, $574 million and $395 million for fiscal 2019, 2018 and 2017, respectively. The estimated annual amortization for intangible assets for fiscal 2020 through 2024 is as follows: $509 million, $442 million, $408 million, $358 million and $329 million. During fiscal 2018, other intangible assets were reduced by $62 million and $133 million in connection with the sale of our China distribution business and reclassification of naviHealth's assets and liabilities to held for sale, respectively.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration